ILMN
Illumina Inc
NASDAQ: ILMN · HEALTHCARE · DIAGNOSTICS & RESEARCH
$142.51
-3.42% today
Updated 2026-06-05
Market cap
$24.35B
P/E ratio
29.21
P/S ratio
5.54x
EPS (TTM)
$5.51
Dividend yield
—
52W range
$86 – $177
Volume
1.6M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
4.0
Growth
C6.5
Quality
B8.5
Profitability
A6.0
Valuation
B6/9
Piotroski F-Score
Moderate
1.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$124.00
-12.99%
12-Month target
$127.31
-10.67%
Intrinsic (DCF)
$276.80
Margin of safety
+57.96%
3 Strong Buy8 Buy5 Hold1 Sell3 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 31.88% — strong efficiency
+ Free cash flow $251.00M — positive
+ 57.96% below intrinsic value
Risks
- Altman Z 1.72 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $4.58B | $4.50B | $4.37B | $4.34B | $4.39B | $4.6B |
| Net income | $-4.40B | $-1.16B | $-1.22B | $850.00M | $134.00M | — |
| EPS | — | — | — | — | $5.51 | $5.12 |
| Free cash flow | $106.00M | $283.00M | $709.00M | $931.00M | $251.00M | — |
| Profit margin | -96.07% | -25.78% | -27.97% | 19.59% | 19.40% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-02 | LECKMAN, PATRICIA | Sale | 318 | $162.00 |
| 2026-06-02 | LECKMAN, PATRICIA | Sale | 290 | $163.02 |
| 2026-06-02 | LECKMAN, PATRICIA | Sale | 176 | $160.66 |
Peer comparison
Smart narrative
Illumina Inc trades at $142.51. representing a P/E of 29.21x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.72, it sits in the distress. TTM revenue stands at $4.39B. with profit margins at 19.40%. Our DCF model estimates intrinsic value at $276.80.
Frequently asked questions
What is Illumina Inc's stock price?
Illumina Inc (ILMN) trades at $142.51, on a P/E of 29.2x and a P/S of 5.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Illumina Inc overvalued?
Illumina Inc carries a Smart Value Score of 56/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $276.80 versus the $142.51 price, a 58.0% margin of safety on a cash flow basis.
What is the price target of Illumina Inc (ILMN)?
The 12-month analyst consensus target is $124.00, about 13.0% below the current $142.51. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of ILMN by 2030?
Our research-backed model puts the 2030 base case at $536.51, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Illumina Inc (ILMN)?
Our DCF model estimates intrinsic value at $276.80, a +58.0% margin of safety versus today's $142.51. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Illumina Inc's revenue?
Illumina Inc's trailing twelve-month revenue is $4.39B, and our model projects it reaching about $6.75B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Illumina Inc's Altman Z-Score is 1.72, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.54x
ROE31.88%
Beta1.49
50D MA$141.72
200D MA$125.43
Shares out0.15B
Float0.15B
Short ratio—
Avg volume1.6M
Performance
1 week+0.00%
1 month+13.88%
3 months+36.08%
YTD+23.76%
1 year—
3 years—
5 years—